Skip to main content
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Multimedia
All Videos
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
Home
Browse by Topic
Issues
Online First
Latest Issue
Issue Archive
Special Issues
PSS Guide
Index
Introduction
Special Series
OFS Summit
Conference Correspondent
SABCS 2023 - HER2+ MBC
SABCS 2023 - HR+/HER2- MBC
ESMO 2023 - Small Cell Lung Cancer
Monthly Minutes
Gastrointestinal Cancer
Lung Cancer
Multiple Myeloma
Multimedia
All Videos
Best Practices in Breast Cancer Therapy | OFS
Interview with the Innovators
Rapid Reactions
Webinars
Subscribe
Practice-Changing Data in NSCLC from ASCO 2021
AACR & ASCO 2021 Midyear Review
Conference Correspondent
Mark A. Socinski, MD
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Dr Mark Socinski provides his insights into important new data on
EGFR
inhibitors and immunotherapy in the first-line setting for NSCLC.
Related Items
Benefits of Dual I-O Therapy in NSCLC and Malignant Pleural Mesothelioma
By
Mark A. Socinski, MD
Conference Correspondent
Dual IO 2021 Year in Review
Benefits of Dual Immune Checkpoint Inhibitor Therapy in Metastatic NSCLC
By
Mark A. Socinski, MD
Conference Correspondent
Dual IO 2021 Year in Review
Comparison of Aumolertinib and Gefitinib in First-Line Treatment of EGFR-Mutated NSCLC
Conference Correspondent
AACR & ASCO 2021 Midyear Review
Two-Year Update from CheckMate-9LA Study of Nivolumab plus Ipilimumab in Advanced NSCLC
Conference Correspondent
AACR & ASCO 2021 Midyear Review